- Home
- CLW vs DMAC Comparison
CLW vs DMAC Comparison
Compare CLW & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- DMAC
- Stock Information
- Founded
- CLW 2005
- DMAC 2000
- Country
- CLW United States
- DMAC United States
- Employees
- CLW N/A
- DMAC N/A
- Industry
- CLW Paper
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CLW Basic Materials
- DMAC Health Care
- Exchange
- CLW Nasdaq
- DMAC Nasdaq
- Market Cap
- CLW 348.3M
- DMAC 310.1M
- IPO Year
- CLW N/A
- DMAC N/A
- Fundamental
- Price
- CLW $22.07
- DMAC $6.89
- Analyst Decision
- CLW Buy
- DMAC Strong Buy
- Analyst Count
- CLW 1
- DMAC 3
- Target Price
- CLW $36.00
- DMAC $12.33
- AVG Volume (30 Days)
- CLW 175.6K
- DMAC 448.5K
- Earning Date
- CLW 11-03-2025
- DMAC 11-12-2025
- Dividend Yield
- CLW N/A
- DMAC N/A
- EPS Growth
- CLW 345.10
- DMAC N/A
- EPS
- CLW 12.12
- DMAC N/A
- Revenue
- CLW $1,550,400,000.00
- DMAC N/A
- Revenue This Year
- CLW $12.75
- DMAC N/A
- Revenue Next Year
- CLW $1.60
- DMAC N/A
- P/E Ratio
- CLW $1.74
- DMAC N/A
- Revenue Growth
- CLW 34.73
- DMAC N/A
- 52 Week Low
- CLW $20.84
- DMAC $3.19
- 52 Week High
- CLW $33.57
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- CLW 46.66
- DMAC 64.26
- Support Level
- CLW $21.07
- DMAC $6.83
- Resistance Level
- CLW $22.70
- DMAC $7.41
- Average True Range (ATR)
- CLW 0.62
- DMAC 0.43
- MACD
- CLW 0.20
- DMAC 0.01
- Stochastic Oscillator
- CLW 50.57
- DMAC 74.90
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.